Medtronic (MDT) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

Medtronic Revenue Highlights


Latest Revenue (Y)

$32.36B

Latest Revenue (Q)

$7.92B

Main Segment (Y)

Cardiac and Vascular Group

Main Geography (Y)

Japan, Australia, New Zealand, Korea, Canada, and Western Europe

Medtronic Revenue by Period


Medtronic Revenue by Year

DateRevenueChange
2024-04-26$32.36B3.64%
2023-04-28$31.23B-1.45%
2022-04-29$31.69B5.21%
2021-04-30$30.12B4.16%
2020-04-24$28.91B-5.38%
2019-04-26$30.56B2.02%
2018-04-27$29.95B0.82%
2017-04-28$29.71B3.04%
2016-04-29$28.83B42.31%
2015-04-24$20.26B19.15%
2014-04-30$17.00B2.50%
2013-04-30$16.59B2.51%
2012-04-30$16.18B1.58%
2011-04-30$15.93B0.73%
2010-04-30$15.82B8.34%
2009-04-30$14.60B8.02%
2008-04-30$13.52B9.89%
2007-04-30$12.30B8.92%
2006-04-30$11.29B12.31%
2005-04-30$10.05B10.65%
2004-04-30$9.09B18.55%
2003-04-30$7.67B19.57%
2002-04-30$6.41B15.47%
2001-04-30$5.55B10.71%
2000-04-30$5.01B21.30%
1999-04-30$4.13B58.71%
1998-04-30$2.60B6.83%
1997-04-30$2.44B12.41%
1996-04-30$2.17B24.49%
1995-04-30$1.74B25.27%
1994-04-30$1.39B-

Medtronic generated $32.36B in revenue during NA 2024, up 3.64% compared to the previous quarter, and up 105.91% compared to the same period a year ago.

Medtronic Revenue by Quarter

DateRevenueChange
2024-07-26$7.92B-7.85%
2024-04-26$8.59B6.18%
2024-01-26$8.09B1.32%
2023-10-27$7.98B3.66%
2023-07-28$7.70B-9.85%
2023-04-28$8.54B10.57%
2023-01-27$7.73B1.87%
2022-10-28$7.58B2.90%
2022-07-29$7.37B-8.88%
2022-04-29$8.09B4.20%
2022-01-28$7.76B-1.07%
2021-10-29$7.85B-1.75%
2021-07-30$7.99B-2.45%
2021-04-30$8.19B5.31%
2021-01-29$7.78B1.67%
2020-10-30$7.65B17.52%
2020-07-31$6.51B8.49%
2020-04-24$6.00B-22.28%
2020-01-24$7.72B0.14%
2019-10-25$7.71B2.84%
2019-07-26$7.49B-8.02%
2019-04-26$8.15B7.95%
2019-01-25$7.55B0.87%
2018-10-26$7.48B1.31%
2018-07-27$7.38B-9.33%
2018-04-27$8.14B10.52%
2018-01-26$7.37B4.52%
2017-10-27$7.05B-4.60%
2017-07-28$7.39B-6.64%
2017-04-28$7.92B8.69%
2017-01-27$7.28B-0.84%
2016-10-28$7.34B2.50%
2016-07-29$7.17B-5.30%
2016-04-29$7.57B9.13%
2016-01-29$6.93B-1.76%
2015-10-30$7.06B-2.97%
2015-07-31$7.27B-0.41%
2015-04-24$7.30B69.15%
2015-01-23$4.32B-1.10%
2014-10-31$4.37B2.18%
2014-07-31$4.27B-6.40%
2014-04-30$4.57B9.66%
2014-01-31$4.16B-0.74%
2013-10-31$4.19B2.72%
2013-07-31$4.08B-8.45%
2013-04-30$4.46B10.75%
2013-01-31$4.03B-1.66%
2012-10-31$4.09B2.17%
2012-07-31$4.01B-6.73%
2012-04-30$4.30B9.67%
2012-01-31$3.92B-5.18%
2011-10-31$4.13B2.05%
2011-07-31$4.05B-5.73%
2011-04-30$4.29B8.43%
2011-01-31$3.96B1.49%
2010-10-31$3.90B3.45%
2010-07-31$3.77B-10.08%
2010-04-30$4.20B8.96%
2010-01-31$3.85B0.34%
2009-10-31$3.84B-2.42%
2009-07-31$3.93B2.72%
2009-04-30$3.83B9.59%
2009-01-31$3.49B-2.13%
2008-10-31$3.57B-3.67%
2008-07-31$3.71B-3.99%
2008-04-30$3.86B13.36%
2008-01-31$3.40B-

Medtronic generated $7.92B in revenue during Q1 2025, up -7.85% compared to the previous quarter, and up 92.64% compared to the same period a year ago.

Medtronic Revenue Breakdown


Medtronic Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceApr 24Apr 23Apr 22Apr 21Apr 20
Diabetes Group$2.49B$2.26B---
Cardiac and Vascular Group$11.83B$11.57B$5.06B--
Medical Surgical$8.42B$8.43B---
Neuroscience Group$9.41B$8.96B---
Neuroscience Portfolio-$8.96B$5.75B$5.46B-
Medical Surgical Portfolio-$8.43B$3.86B$3.65B-
Diabetes Operating Unit-$2.26B---
Cardiovascular-$11.57B$5.54B--
Cardiovascular Portfolio---$141.00M-
Restorative Therapies Group----$5.12B
Minimally Invasive Therapies Group----$3.53B

Medtronic's latest annual revenue breakdown by segment (product or service), as of Apr 24: Cardiac and Vascular Group (36.81%), Neuroscience Group (29.26%), Medical Surgical (26.19%), and Diabetes Group (7.74%).

Quarterly Revenue by Product

Product/ServiceJul 24Apr 24Oct 23Jul 23Apr 23Jan 23Oct 22Jul 22Apr 22Jan 22Oct 21Jul 21Jan 21Oct 20Jul 20Apr 20Jan 20Oct 19Jul 19Apr 19
Neuroscience Group$2.32B$4.90B$2.29B$4.44B$1.51B$1.51B$1.42B$1.40B$1.39B$1.45B----------
Diabetes Group$647.00M$947.00M$963.00M$1.16B----------------
Cardiac and Vascular Group$3.01B$6.06B$1.27B$1.38B$1.21B$880.00M$1.37B$1.46B$1.36B$1.51B----------
Medical Surgical$2.00B$4.24B$2.14B$4.08B$965.00M$905.00M$843.00M$990.00M$970.00M$990.00M----------
Other--$22.00M$32.00M----------------
Cardiovascular--$2.92B$5.70B$9.23B$1.38B$1.42B$1.30B$1.46B$1.30B$1.37B$1.42B--------
Minimally Invasive Therapies Group------------$959.00M$996.00M$722.00M$763.00M$934.00M$922.00M$913.00M$971.00M
Restorative Therapies Group------------$1.40B$1.40B$1.14B$935.00M$1.41B$1.44B$1.34B$1.47B

Medtronic's latest quarterly revenue breakdown by segment (product or service), as of Jul 24: Cardiac and Vascular Group (37.74%), Neuroscience Group (29.08%), Medical Surgical (25.05%), and Diabetes Group (8.12%).

Medtronic Revenue Breakdown by Country

Annual Revenue by Country

CountryApr 24Apr 23Apr 22Apr 21Apr 20
Middle East, Africa, Latin America, Eastern Europe, and Asia, Excluding Japan and Korea$5.82B$5.45B---
Japan, Australia, New Zealand, Korea, Canada, and Western Europe$9.98B$9.41B---
Total Other Countries, Excluding United States and Ireland-$14.76B$15.45B$14.49B$13.91B
Total Other Countries, Excluding Ireland-$31.13B$31.59B$30.02B$28.83B
IRELAND-$98.00M$101.00M$100.00M$85.00M
Medical Surgical Portfolio--$3.86B--
Cardiovascular--$5.54B--
Neuroscience Portfolio--$5.75B--

Medtronic's latest annual revenue breakdown by geography, as of Apr 24: Japan, Australia, New Zealand, Korea, Canada, and Western Europe (63.15%), and Middle East, Africa, Latin America, Eastern Europe, and Asia, Excluding Japan and Korea (36.85%).

Quarterly Revenue by Country

CountryJul 24Apr 24Oct 23Jul 23Apr 23Jan 23Oct 22Jul 22Apr 22Jan 22Oct 21Jul 21Apr 21Jan 21Oct 20Jul 20Apr 20Jan 20Oct 19Jul 19
IRELAND$30.00M$29.00M$29.00M$27.00M$23.00M$25.00M$23.00M$25.00M$24.00M$27.00M$26.00M$26.00M$25.00M$24.00M$24.00M$19.00M$22.00M$23.00M$20.00M-
UNITED STATES$4.08B$4.18B------------------
Japan, Australia, New Zealand, Korea, Canada, and Western Europe-$5.15B$2.37B$2.67B----------------
Middle East, Africa, Latin America, Eastern Europe, and Asia, Excluding Japan and Korea-$3.07B$1.44B$1.33B----------------
Total Other Countries, Excluding Ireland--$7.96B$7.67B$8.52B$7.70B$7.56B$7.35B$8.06B$7.74B$7.82B$7.96B$8.16B$7.75B$7.62B$6.48B$5.98B$7.70B$7.68B$7.47B
Total Other Countries, Excluding United States and Ireland--$3.78B$3.75B$4.04B$3.64B$3.49B$3.58B$3.97B$3.80B$3.82B$3.86B$3.98B$3.81B$3.57B$3.13B$3.13B$3.67B$3.55B$3.56B
Medical Surgical-----$965.00M--------------
Neuroscience Group-----$1.51B--------------
Cardiovascular-----$1.38B--------------

Medtronic's latest quarterly revenue breakdown by geography, as of Jul 24: UNITED STATES (99.27%), and IRELAND (0.73%).

Medtronic Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
ABTAbbott Laboratories$40.11B$10.63B
MDTMedtronic$32.36B$7.92B
SYKStryker$20.50B$5.49B
EWEdwards Lifesciences$6.00B$1.39B
ALGNAlign$3.86B$1.03B
DXCMDexCom$3.62B$994.20M
ZBHZimmer Biomet$1.94B$143.40M
PODDInsulet$1.70B$488.50M
TNDMTandem Diabetes Care$747.72M$331.03M

MDT Revenue FAQ


Medtronic's yearly revenue for 2024 was $32.36B, representing an increase of 3.64% compared to 2023. The company's yearly revenue for 2023 was $31.23B, representing a decrease of -1.45% compared to 2022. MDT's yearly revenue for 2022 was $31.69B, representing an increase of 5.21% compared to 2021.

Medtronic's quarterly revenue for Q1 2025 was $7.92B, a -7.85% decrease from the previous quarter (Q4 2024), and a 2.77% increase year-over-year (Q1 2024). The company's quarterly revenue for Q4 2024 was $8.59B, a 6.18% increase from the previous quarter (Q3 2024), and a 0.53% increase year-over-year (Q4 2023). MDT's quarterly revenue for Q3 2024 was $8.09B, a 1.32% increase from the previous quarter (Q2 2024), and a 4.68% increase year-over-year (Q3 2023).

Medtronic's revenue growth rate for the last 3 years (2022-2024) was 2.14%, and for the last 5 years (2020-2024) was 11.94%.

Medtronic's revenue streams in r 24 are Diabetes Group, Cardiac and Vascular Group, Medical Surgical, and Neuroscience Group. Diabetes Group generated $2.49B in revenue, accounting 7.74% of the company's total revenue, up 9.99% year-over-year. Cardiac and Vascular Group generated $11.83B in revenue, accounting 36.81% of the company's total revenue, up 2.23% year-over-year. Medical Surgical generated $8.42B in revenue, accounting 26.19% of the company's total revenue, down -0.19% year-over-year. Neuroscience Group generated $9.41B in revenue, accounting 29.26% of the company's total revenue, up 4.99% year-over-year.

For the fiscal year ending Apr 24, the largest source of revenue of Medtronic was Cardiac and Vascular Group. This segment made a revenue of $11.83B, representing 36.81% of the company's total revenue.